公开(公告)号：US11261233B2

公开(公告)日：2022-03-01

申请号：US16333888

申请日：2017-09-19

申请人： ONCOC4, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Wei Wu ,  Xuexiang Du ,  Mingyue Liu ,  Fei Tang

IPC分类号： C07K14/705 ,  C07K16/46 ,  A61K38/00 ,  A61P37/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  C07K14/00 ,  A61K39/00

摘要： This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

公开(公告)号：US11116726B2

公开(公告)日：2021-09-14

申请号：US15774217

申请日：2016-11-09

申请人： CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Yin Wang ,  Yan Liu ,  Christopher Bailey ,  Pan Zheng

IPC分类号： A61K9/127 ,  A61K38/16 ,  A61K47/69 ,  A61K35/74 ,  A61P37/02 ,  A61P35/02

摘要： A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

公开(公告)号：US20210214458A1

公开(公告)日：2021-07-15

申请号：US17055248

申请日：2019-05-13

申请人： ONCOIMMUNE, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Rhonda Flores ,  Hung-Yen Chou ,  Zhihong Xue ,  Peiying Ye ,  Martin Devenport

IPC分类号： C07K16/28 ,  A61P35/00

摘要： Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.

公开(公告)号：US20210047410A1

公开(公告)日：2021-02-18

申请号：US16967065

申请日：2019-01-29

申请人： oncolmmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC分类号： C07K16/28 ,  A61P35/00 ,  C12N5/071 ,  C12N5/0783 ,  G01N33/58

摘要： The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US20220000974A1

公开(公告)日：2022-01-06

申请号：US17428784

申请日：2020-02-05

申请人： Oncolmmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Xu Wang ,  Martin Devenport

IPC分类号： A61K38/17 ,  C07K14/705 ,  A61P3/06 ,  A61P3/10

摘要： Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.

公开(公告)号：US11629188B2

公开(公告)日：2023-04-18

申请号：US16803972

申请日：2020-02-27

申请人： ONCOC4, INC.

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00

摘要： This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US12129299B2

公开(公告)日：2024-10-29

申请号：US16967079

申请日：2019-01-29

申请人： ONCOC4, INC. ,  University of Maryland, Baltimore

发明人： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 ,  C07K16/2827 ,  C07K2317/565 ,  C07K2317/71

摘要： This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US20240139280A1

公开(公告)日：2024-05-02

申请号：US18286334

申请日：2022-04-13

申请人： ONCOC4, INC. ,  University of Maryland, Baltimore

发明人： Yin Wang ,  Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Yan Liu ,  Christopher Bailey

IPC分类号： A61K38/12 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K38/12 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

摘要： The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.